Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Nutritional Biochemistry
• Genomics

Background:

• Observational studies suggest selenium's role in non-alcoholic fatty liver disease (NAFLD) pathogenesis.
• Transcriptomic analysis can elucidate selenium's involvement in NAFLD etiology and progression.

Purpose of the Study:

• To compare gene expression of selenoprotein pathways in healthy livers versus NAFLD livers.
• To investigate the relationship between selenium, gene expression, and iron metabolism in NAFLD.

Main Methods:

• Utilized publicly available gene expression databases.
• Analyzed four datasets measuring global gene expression in liver samples.
• Focused on five selenoprotein-related pathways (164 genes) in steatosis, non-alcoholic steatohepatitis (NASH), and control groups (healthy obese and healthy non-obese).

Main Results:

• TXNRD3 gene expression was lower in NAFLD groups compared to healthy obese controls.
• SCLY and SELENOO showed lower expression in NASH compared to healthy controls.
• SELENOM, DIO1, GPX2, and GPX3 were highly expressed in NASH versus healthy obese controls.
• NAFLD livers exhibited lower expression of iron transporters and higher expression of ferritin subunits, indicating disrupted iron metabolism.
• Gene expression variations correlate with NAFLD progression risk.

Conclusions:

• The NAFLD liver may possess lower selenium levels, potentially disrupting iron metabolism.
• Gene expression patterns in selenoprotein pathways are associated with NAFLD and its progression.